Equity news
8-
Dlf: citi maintains a buy on dlf with a reduced target price of ₹770, citing q4fy26 pre-sales of ₹201 billion despite geopolitical headwinds, sustained ultra-luxury demand with 32 dahlias units sold, fy27 pre-sales guidance of ₹200 billion backed by four major launches, and strong structural tailwinds from dlf’s premium brand positioning and customer preference for quality developers.
-
Dlf: hsbc maintains a buy on dlf with a target price of ₹920, citing pre-sales beating expectations driven by strong momentum in dahlias, a steadily growing cash pile, and confidence that the stable commercial portfolio and strong value-creation track record will continue to support residential growth.
-
Fusion finance: aims for 20-25% growth, confirms rs. 10,000 crore aum goal by march 2027, and projects credit costs of 3.25-3.75%, says md & ceo.
-
Vishal mega mart: jefferies maintains a buy on vishal mega mart with a target price of ₹160, citing strong acceleration in same-store sales growth to ~12%, robust revenue growth and ~40% yoy pre-ind as ebitda growth, increasing contribution from own brands, and management confidence in strong earnings growth despite near-term input cost pressures from geopolitical uncertainty.
-
Vishal mega mart: hsbc maintains a buy on vishal mega mart with a target price of ₹170, citing strong q4 same-store sales growth of 12.1%, continued ebitda expansion of 39% yoy despite a slight margin miss from higher discounts, management’s confidence in outperforming during inflationary periods, and its preference for the stock within consumer discretionary picks.
-
Icici prudential life: nomura maintains a buy on icici prudential life with a target price of ₹680, noting the stock has underperformed sharply with a 21% decline versus the nifty 50’s 10% fall in cy26 amid concerns over prudential’s potential exit, creating an attractive opportunity after the correction.
-
Icici prudential life: morgan stanley remains overweight on icici prudential life with a target price of ₹670, stating that prima facie the transaction is unlikely to have any fundamental impact on the company’s operations or long-term business prospects.
-
Alembic pharma: targets low double-digit revenue growth for fy27, with international generics expected to grow in the low to mid-teen range, api business anticipated to grow in high single or low double-digit, and india business aiming for growth aligned with market trends.
